TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic stem ce...
Read moreLa revista científica Nature Chemistry destaca en portada el trabajo de un equipo investigador de la Universidad de Barcelona que ha desarrollado un método computacional más eficaz para identificar...
Read moreTiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose deri...
Read moreCobo Scientific is offering products and services from leading life science companies within the BioMedical and Drug Discovery field. It was founded in January 2017 and is working as an European comme...
Read moreLa Dra. Silvia Murillo-Cuesta, investigadora de la U761 CIBERER que lidera la Prof. Isabel Varela-Nieto, es la primera firmante de un estudio publicado en Journal of Visualized Experiments que compara...
Read moreSince the discovery of the potential use of nanomaterials in the field of nanomedicine, scientists have tried to develop nano-drugs able to travel through the body and specifically recognize with grea...
Read moreMinoryx Therapeutics – a drug development company specialized in the discovery and development of new drugs for orphan diseases, which has R& D laboratories at the Barcelona Science Park– announce...
Read moreEuropean Medicines Agency published Module V of Good Vigilance Practices in 2012 and it was later revised in April 2014. The main objective of this module is to harmonize the development of the Risk M...
Read moreEl aumento de la resistencia de las bacterias patógenas a la acción de los antibióticos ha originado que la Organización Mundial de la Salud (OMS) solicite a la comunidad científica la búsqueda ...
Read moreAs part of this agreement, studies will be carried out based on the use of cellular models from various types of tumours as well as the CNIO's platform of tumour stem cells. An important part of the s...
Read moreLa eficacia y la seguridad a largo plazo de los inhibidores de la tirosincinasa BCR/ABL (ITKs) en el tratamiento de los pacientes con leucemia mieloide crónica (LMC), son unos de los principales o...
Read moreScientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant. The artemisinin-based combination therapy (ACT) is the standard treatment for malari...
Read more